Forbion is a global life sciences venture capital firm headquartered in Naarden, the Netherlands, with additional offices in Munich and Boston. Founded two decades ago, the firm invests across the full lifecycle of biopharmaceutical innovation, backing therapeutics companies from company creation through late-stage growth. Forbion has financed 142 companies to date and manages roughly $8.4 billion in assets across 12 funds.
Forbion invests across the full continuum of biopharmaceutical innovation, from company creation to late-stage growth. Forbion Ventures Fund VIII builds and backs innovative therapeutics-focused biotech companies, both newly founded and existing, addressing high unmet medical needs.
Forbion Growth Opportunities Fund IV targets later-stage biopharma companies in Europe and North America developing novel therapies for serious diseases.
Beyond human health, Forbion also invests in planetary health through its separate BioEconomy strategy, backing biotechnologies and green chemistries that scale industrial sustainability.
In October 2026, Forbion closed $2.6 billion across two new funds: Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII.
The raise exceeds the roughly $2.2 billion Forbion closed across the predecessor Growth Opportunities Fund III and Ventures Fund VII in 2024.
The funds are backed by a mix of long-standing and new limited partners, including MN, PGGM, KfW Capital, the Kauffman Foundation, and Eli Lilly and Company.
Leadership
Sander Slootweg, Managing Partner and co-founder, and Dirk Kersten, Managing Partner, lead Forbion's investment team alongside Robbert van de Griendt, General Partner, Investor Relations and Impact.
Investment Strategy
Forbion pairs early-stage company creation with growth-stage capital, writing checks that historically average around $10 million but can scale to roughly $75 million per deal for later-stage opportunities through its Growth Opportunities strategy.
The firm takes an active, hands-on approach, often serving as lead investor and board member, and draws on a 20-year track record spanning 12 funds.
Notable Investments
Notable Exits
Sander Slootweg, Managing Partner and Co-Founder
sander.slootweg@forbion.com
Martien van Osch, Managing Partner
martien.van.osch@forbion.com
John Montana, Operating Partner
john.montana@forbion.com
Regina Salvat, Principal
regina.salvat@forbion.com
Carlo Incerti, Operating Partner
carlo.incerti@forbion.com
Wouter Joustra, General Partner
wouter.joustra@forbion.com
Jasper Bos, General Partner
jasper.bos@forbion.com
Goukben Koca, Venture Partner
goekben.koca@forbion.com
Alexander Hoffmann, General Partner
alex.hoffmann@forbion.com
Carolin Lanfer, Senior Associate
carolin.lanfer@forbion.com
Morgan Haller, Principal
morgan.haller@forbion.com
Vincent Loon, Investor
vincent.loon@forbion.com
Melanie Almedia, Associate
melanie.de.almeida@forbion.com
Netherlands
